These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17339744)

  • 1. [Relationship between sevelamer HCl and vascular calcification].
    Uemura K; Kakuta T; Saito A
    Clin Calcium; 2007 Mar; 17(3):392-8. PubMed ID: 17339744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].
    Masho Y; Shigematsu T
    Clin Calcium; 2007 Mar; 17(3):354-9. PubMed ID: 17339739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
    Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR; Massry SG;
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular calcification and disordered mineral metabolism in dialysis patients.
    Kalpakian MA; Mehrotra R
    Semin Dial; 2007; 20(2):139-43. PubMed ID: 17374088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Control of calcium and phosphate in hemodialysis patients].
    Eriguchi R; Takei S; Satou Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
    Uribarri J;
    Semin Dial; 2004; 17(5):349-50. PubMed ID: 15461740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of progressive vascular calcification in haemodialysis patients.
    Chertow GM; Raggi P; Chasan-Taber S; Bommer J; Holzer H; Burke SK
    Nephrol Dial Transplant; 2004 Jun; 19(6):1489-96. PubMed ID: 15102961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.